喜訊 | Renata公司蒞臨我司開展原料藥現場審計，合作信心再添強援

Great News | Renata Company Conducts On-Site Audit of APIs at Our Company, Further Strengthening Confidence in Cooperation

2025年10月21日，孟加拉國知名制藥企業Renata有限公司（以下簡稱“Renata公司”）審計團隊一行，蒞臨我司就原料藥生產與質量管理體系開展專項現場審計。該公司目前已有多個吸入制劑用 API 與我司建立了合作，作為孟加拉國制藥行業的領軍企業，Renata公司在全球醫藥市場擁有廣泛的影響力與嚴格的供應商準入標準。此次現場審計，其團隊依據GMP及自身核心采購標準，對我司進行了全鏈條、多維度的細致核查。審計范圍涵蓋原料藥生產車間的設施設備運行狀況、生產工藝流程的規范性、原輔料及成品的檢驗檢測、質量追溯系統的完整性、倉儲物流的合規管理，以及數據完整性等關鍵環節。經過為期一天的嚴謹核查與深度交流，審計團隊對我司在生產合規性、質量管理能力及供應鏈保障等方面的表現給予高度評價與認可，為雙方深化戰略合作奠定了堅實基礎。

On October 21, 2025, an audit team from Renata Limited ("Renata" for short), a renowned pharmaceutical enterprise in Bangladesh, visited our company to conduct a special on-site audit on the production and quality management system of APIs. Currently, the company has established cooperation with us on multiple APIs for inhalation formulations. As a leading enterprise in Bangladesh's pharmaceutical industry, Renata enjoys extensive influence in the global pharmaceutical market and maintains stringent supplier access standards. During this on-site audit, the team conducted a full-chain, multi-dimensional and meticulous verification of our company in accordance with GMP and its own core procurement criteria. The audit scope covered key links including the operation status of facilities and equipment in API production workshops, the standardization of production processes, the inspection and testing of raw materials, auxiliary materials and finished products, the integrity of the quality traceability system, the compliant management of warehousing and logistics, as well as data integrity. After a full day of rigorous verification and in-depth communication, the audit team highly recognized and praised our company's performance in production compliance, quality management capabilities and supply chain security, laying a solid foundation for the deepening of strategic cooperation between the two parties.

我司也將以此為新起點，持續深耕醫藥領域，堅守質量底線，強化創新驅動，為全球醫藥健康事業的發展貢獻堅實力量。

Taking this as a new starting point, our company will continue to deepen its presence in the pharmaceutical field, uphold the bottom line of quality, strengthen innovation-driven development, and contribute solid strength to the progress of the global pharmaceutical and healthcare industry.